NCT05629598 - A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia . | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

August 16, 2023

Conditions

Renal Anemia

Interventions

BIOLOGICAL

Recombinant human erythropoietin injection

The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

BIOLOGICAL

Human erythropoietin injection

Refer to the product instructions

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospitial,College of Medicine,Zhejiang University, Hanzhou